News & Updates

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

01 Feb 2022

At a dose of 6 mg, brolucizumab yields substantial visual gains and anatomical improvements in patients with diabetic macular oedema without increasing the risk of serious adverse ocular events when compared with aflibercept, according to data from two phase III trials.

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

01 Feb 2022

Plecanatide may be safely administered with antacid

31 Jan 2022 by

Acid suppression therapy appears to exert no meaningful effect on the efficacy or safety of plecanatide when administered concomitantly, according to a study.

Plecanatide may be safely administered with antacid

31 Jan 2022

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

31 Jan 2022

Treatment with either low- or high-dose secukinumab is effective and well tolerated in paediatric patients with moderate to severe plaque psoriasis, a study has shown.

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

31 Jan 2022

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022 by

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022 by

While a fourth dose of the COVID-19 vaccine boosts antibodies to levels that are higher than the third dose, it is not enough to protect against Omicron infections, according to preliminary data from Israel.

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022 by

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022

Erenumab effective for migraine regardless of aura status

28 Jan 2022 by

In a post hoc analysis, use of the anti-CGRP* receptor monoclonal antibody erenumab led to reduced migraine frequency and AMSM** days in individuals with migraine with and without a history of aura.

Erenumab effective for migraine regardless of aura status

28 Jan 2022

Dronedarone better than sotalol in post-AF ablation setting

27 Jan 2022 by

Treatment with dronedarone following atrial fibrillation (AF) ablation appears to lead to a reduced risk of cardiovascular hospitalization as well as lower rates of combined proarrhythmia when compared with sotalol, as shown in a recent study.